Status: Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Participants needed: 500
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Revolution Medicines, Inc.Updated: Jun 22, 2026Locations: 34
Eligibility criteria
At least 18 years old and has provided informed consent. [+7]
Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors)... [+3]